Travere Therapeutics (TVTX) News Today $18.37 -0.10 (-0.54%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $22.00January 18 at 3:23 AM | americanbankingnews.comHC Wainwright Issues Pessimistic Forecast for TVTX EarningsJanuary 18 at 1:17 AM | americanbankingnews.comFY2024 EPS Estimate for Travere Therapeutics Cut by AnalystTravere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - Equities research analysts at HC Wainwright lowered their FY2024 earnings per share estimates for Travere Therapeutics in a report released on Wednesday, January 15th. HC Wainwright analyst E. Arce now anticipates that the company will postJanuary 17 at 6:40 AM | marketbeat.comFY2029 Earnings Estimate for TVTX Issued By HC WainwrightTravere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - Equities research analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Travere Therapeutics in a research note issued to investors on Wednesday, January 15th. HC Wainwright analyst E. Arce forecasts that the companJanuary 16 at 7:47 AM | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Stock Price Expected to Rise, HC Wainwright Analyst SaysHC Wainwright raised their price target on Travere Therapeutics from $18.00 to $22.00 and gave the stock a "buy" rating in a research report on Wednesday.January 15 at 7:15 AM | marketbeat.comTravere Therapeutics price target raised to $45 from $41 at GuggenheimJanuary 14, 2025 | markets.businessinsider.comTravere Therapeutics (NASDAQ:TVTX) Shares Down 4.2% - Should You Sell?Travere Therapeutics (NASDAQ:TVTX) Stock Price Down 4.2% - Should You Sell?January 14, 2025 | marketbeat.comTravere Therapeutics sees FY24 net product sales approx $227MJanuary 13, 2025 | markets.businessinsider.comTravere Therapeutics (NASDAQ:TVTX) Now Covered by Cantor FitzgeraldJanuary 13, 2025 | americanbankingnews.comCantor Fitzgerald Initiates Coverage on Travere Therapeutics (NASDAQ:TVTX)Cantor Fitzgerald began coverage on shares of Travere Therapeutics in a research note on Friday. They issued an "overweight" rating on the stock.January 10, 2025 | marketbeat.comJula Inrig Sells 2,066 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) StockJanuary 8, 2025 | americanbankingnews.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Insider Jula Inrig Sells 2,066 SharesJanuary 7, 2025 | insidertrades.comInsider Selling: Travere Therapeutics, Inc. (NASDAQ:TVTX) Insider Sells 2,066 Shares of StockTravere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider Jula Inrig sold 2,066 shares of Travere Therapeutics stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $19.10, for a total value of $39,460.60. Following the transaction, the insider now directly owns 59,883 shares in the company, valued at approximately $1,143,765.30. The trade was a 3.34 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.January 6, 2025 | marketbeat.comBank of America Securities Keeps Their Buy Rating on Travere Therapeutics (TVTX)January 6, 2025 | markets.businessinsider.comTravere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | globenewswire.comTravere Therapeutics (NASDAQ:TVTX) Trading Up 7.2% - Here's WhyTravere Therapeutics (NASDAQ:TVTX) Trading Up 7.2% - Should You Buy?January 2, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Rating of "Moderate Buy" by AnalystsTravere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) has received an average recommendation of "Moderate Buy" from the twelve analysts that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and eleven have assigned a bDecember 30, 2024 | marketbeat.comGeode Capital Management LLC Grows Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)Geode Capital Management LLC lifted its holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 3.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,731,045 shares of the company's stocDecember 28, 2024 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sells $258,300.00 in StockTravere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) CAO Sandra Calvin sold 15,000 shares of the business's stock in a transaction that occurred on Thursday, December 26th. The stock was sold at an average price of $17.22, for a total transaction of $258,300.00. Following the completion of the transaction, the chief accounting officer now owns 54,927 shares in the company, valued at $945,842.94. This trade represents a 21.45 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.December 27, 2024 | marketbeat.comInvesting in Travere Therapeutics (NASDAQ:TVTX) a year ago would have delivered you a 82% gainDecember 26, 2024 | finance.yahoo.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Holdings Decreased by State Street CorpState Street Corp lowered its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 22.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,736,696 shares of the company's stock after selling 773,981 sharesDecember 21, 2024 | marketbeat.comXTX Topco Ltd Cuts Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)XTX Topco Ltd cut its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 73.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 14,205 shares of the company's stock after selling 40December 20, 2024 | marketbeat.comTravere Therapeutics: Cautiously Bullish Based On Improving RevenueDecember 19, 2024 | seekingalpha.comHomocystinuria Therapeutics Market Research 2024: Insights About 3+ Companies and 3+ Pipeline Drugs Featuring Travere Therapeutics and Syntis BioDecember 18, 2024 | globenewswire.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Position Trimmed by Y Intercept Hong Kong LtdY Intercept Hong Kong Ltd reduced its holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 70.4% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 28,217 shares of the company's stock after selling 67,065 shares during the quaDecember 17, 2024 | marketbeat.comFmr LLC Grows Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)Fmr LLC increased its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 27.5% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 147,416 shares of the company's stock after purchasing an additional 31,December 15, 2024 | marketbeat.comTwo Sigma Advisers LP Raises Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)Two Sigma Advisers LP lifted its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 30.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 720,400 shares of the company's stock afteDecember 10, 2024 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Point72 Asia Singapore Pte. Ltd.Point72 Asia Singapore Pte. Ltd. decreased its holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 88.6% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 4,037 shares of the company's stock after sellingDecember 8, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Has $22.25 Million Stake in Travere Therapeutics, Inc. (NASDAQ:TVTX)Jacobs Levy Equity Management Inc. cut its holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 15.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,590,377 shares of the company's stock after selling 299,467 shaDecember 5, 2024 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) have been given an average rating of "Moderate Buy" by the thirteen ratings firms that are currently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and eleven haveDecember 5, 2024 | marketbeat.comParkman Healthcare Partners LLC Grows Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)Parkman Healthcare Partners LLC boosted its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 12.0% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 1,086,067 shares of the company's stock after purchasing an additional 116,175 shares during theDecember 4, 2024 | marketbeat.comHighVista Strategies LLC Sells 72,183 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)HighVista Strategies LLC reduced its holdings in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 32.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 147,233 shares of the company's stock aDecember 3, 2024 | marketbeat.comBellevue Group AG Buys New Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)Bellevue Group AG purchased a new position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 31,000 shares of the company's stock, valued at approximatDecember 2, 2024 | marketbeat.comWalleye Capital LLC Acquires 201,282 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)Walleye Capital LLC increased its holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 70.1% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 488,453 shares of the company's stock after purchasing an additional 201,282 shDecember 1, 2024 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Shares Acquired by Healthcare of Ontario Pension Plan Trust FundHealthcare of Ontario Pension Plan Trust Fund lifted its holdings in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 37.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 843,300 sharesNovember 29, 2024 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sells $221,247.00 in StockNovember 26, 2024 | insidertrades.comTravere Therapeutics to Present at Upcoming Investor ConferencesNovember 25, 2024 | globenewswire.comConnor Clark & Lunn Investment Management Ltd. Purchases 52,985 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)Connor Clark & Lunn Investment Management Ltd. grew its position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 11.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 525,381 shares of the company's stockNovember 23, 2024 | marketbeat.comTravere Therapeutics (TVTX) Gets a Buy from J.P. MorganNovember 21, 2024 | markets.businessinsider.comOppenheimer & Co. Inc. Acquires New Stake in Travere Therapeutics, Inc. (NASDAQ:TVTX)Oppenheimer & Co. Inc. bought a new position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 48,139 shares of the company's stock, valued at approximatelNovember 21, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXNovember 18, 2024 | prnewswire.comMHRA approves Travere’s sparsentan to treat adults with primary IgANNovember 18, 2024 | markets.businessinsider.comLos Angeles Capital Management LLC Sells 56,866 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)Los Angeles Capital Management LLC lowered its holdings in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 67.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 27,951 shares of the company's stock after selling 56,866 shares during the pNovember 18, 2024 | marketbeat.comPiper Sandler Forecasts Strong Price Appreciation for Travere Therapeutics (NASDAQ:TVTX) StockPiper Sandler increased their price target on Travere Therapeutics from $12.00 to $22.00 and gave the company a "neutral" rating in a research report on Thursday.November 14, 2024 | marketbeat.comTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 13, 2024 | globenewswire.com3 Under-the-Radar Healthcare Companies (TVTX)While established healthcare firms are among the most stable stocks in the sector, up-and-coming companies can offer the potential for greater gains.November 11, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXNovember 10, 2024 | prnewswire.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Receives Average Rating of "Moderate Buy" from AnalystsShares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the thirteen analysts that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and eleven have giveNovember 10, 2024 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Reaches New 12-Month High - Here's What HappenedTravere Therapeutics (NASDAQ:TVTX) Hits New 12-Month High - Here's What HappenedNovember 8, 2024 | marketbeat.comTravere Therapeutics Announces Pricing of Public Offering of Common StockNovember 7, 2024 | globenewswire.com Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address TVTX Media Mentions By Week TVTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TVTX News Sentiment▼0.650.68▲Average Medical News Sentiment TVTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TVTX Articles This Week▼115▲TVTX Articles Average Week Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Elanco Animal Health News Today Cytokinetics News Today Nuvalent News Today Grifols News Today Viking Therapeutics News Today TG Therapeutics News Today Krystal Biotech News Today Axsome Therapeutics News Today Organon & Co. News Today Alvotech News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TVTX) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredInvesting Tools You’ll Need for 2025Investing Tools You’ll Need for 2025 Charles Payne Shares His #1 Strategy for 2025 Unstoppable Prosperity | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
